HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Our initial program, HIL-214, is a virus-like particle based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
We initiated a Phase 2b study, NEST-IN1, in the second quarter of 2022 to evaluate the safety, immunogenicity, and efficacy of HIL-214 in infants. We reported interim safety data from this trial for the first 203 subjects in the second quarter of 2022, and interim immunogenicity data for the first 203 subjects in the fourth quarter of 2022. Â We expect to report top-line data from NEST-IN1 in the first quarter of 2024. In -addition to infants, we also plan to seek approval of HIL-214 in additional age groups such as older children, adults, and older adults.
HilleVax has assembled a distinguished team with experience in vaccine development, clinical trial operations, manufacturing, and commercialization, including prior experiencing developing HIL-214 at Takeda Pharmaceuticals.
